DOI:
10.1039/D1TB01001H
(Review Article)
J. Mater. Chem. B, 2021,
9, 7117-7131
Manganese oxide nanomaterials boost cancer immunotherapy
Received
5th May 2021
, Accepted 25th June 2021
First published on 26th June 2021
Abstract
Immunotherapy, a strategy that leverages the host immune function to fight against cancer, plays an increasingly important role in clinical tumor therapy. In spite of the great success achieved in not only clinical treatment but also basic research, cancer immunotherapy still faces many huge challenges. Manganese oxide nanomaterials (MONs), as ideal tumor microenvironment (TME)-responsive biomaterials, are able to dramatically elicit anti-tumor immune responses in multiple ways, indicating great prospects for immunotherapy. In this review, on the basis of different mechanisms to boost immunotherapy, major highlighted topics are presented, covering adjusting an immunosuppressive TME by generating O2 (like O2-sensitized photodynamic therapy (PDT), programmed cell death ligand-1 (PD-L1) expression downregulation, reprogramming tumor-associated macrophages (TAMs), and restraining tumor angiogenesis and lactic acid exhaustion), inducing immunogenic cell death (ICD), photothermal therapy (PTT) induction, activating the stimulator of interferon gene (STING) pathway and immunoadjuvants for nanovaccines. We hope that this review will provide holistic understanding about MONs and their application in cancer immunotherapy, and thus pave the way to the translation from bench to bedside in the future.
![image file: d1tb01001h-p1.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-p1.gif)
Binbin Ding
| Binbin Ding was born in Anhui, China, in 1991. He received his BS degree (2015) in Pharmaceutical Engineering from Hefei University of Technology, and his PhD degree (2020) in Inorganic Chemistry under the guidance of Prof. Jun Lin at Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. After graduation, he became Assistant Professor in Prof. Jun Lin's group. His current research focuses on the synthesis and bioapplication of nanoadjuvants. |
![image file: d1tb01001h-p2.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-p2.gif)
Jun Yue
| Jun Yue was born in He’nan, China, in 1983. He received his BS degree in Polymer Materials and Engineering from Zhengzhou University (2007) and PhD degree in Polymer Chemistry and Physics from Changchun Institute of Applied Chemistry (2013). From December 2012 to February 2018, he experienced postdoctoral work in Prof. A. Herrmann's group at the University of Groningen and Prof. Teri Odom's group at Northwestern University, respectively. From March 2018, he was appointed as an associate professor in Biomedical Engineering at Sun Yat-sen University and presently his research interest is focused on the nanofabrication of novel biomaterials for cancer treatment and bioimaging. |
![image file: d1tb01001h-p3.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-p3.gif)
Pan Zheng
| Pan Zheng was born in Anhui, China, in 1991. She received her BS degree (2015) in pharmaceutical engineering from Hefei University of Technology, and her PhD degree (2021) in Polymer Chemistry and Physics under the guidance of Prof. Gao Li at Changchun Institute of Applied Chemistry, Chinese Academy of Sciences. Her current research focuses on the design and preparation of activatable nanomaterials for cancer treatment. |
![image file: d1tb01001h-p4.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-p4.gif)
Ping’an Ma
| Ping’an Ma was born in Jilin, China, in 1982. He received his BS degree in Biology in 2005 at Northeast Normal University, and his PhD degree in Biochemistry in 2010 at Northeast Normal University. After graduation, he became Assistant Professor in Prof. Jun Lin's group and was promoted to Professor in 2020. His research focuses on the synthesis and application of multifunctional inorganic nanoparticles for bioapplication, particularly the design and mechanism of platinum-based anticancer drugs. |
![image file: d1tb01001h-p5.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-p5.gif)
Jun Lin
| Jun Lin was born in Changchun, China, in 1966. He received BS and MS degrees in Jilin University, and a PhD degree in Changchun Institute of Applied Chemistry (1995). His postdoctoral studies were performed at the City University of Hong Kong (1996), Institute of New Materials (Germany, 1997), Virginia Commonwealth University (USA, 1998), and the University of New Orleans (USA, 1999). He has been working as a Professor at CIAC since 2000. His research interests include bulk- and nanostructured luminescent materials and multifunctional composite materials, together with their applications in display, lighting, and biomedical fields. |
1. Introduction
Different from traditional surgery, chemotherapy and radiotherapy, immunotherapy, a strategy that leverages the host immune function to fight against cancer, plays an increasingly important role in clinical tumor therapy and is considered as one of the most promising treatments for curing cancer thanks to its abscopal effects that inhibit and eradicate metastatic tumors.1–5 Currently, various strategies for immunotherapy are being developed, such as adoptive cell therapy, immune checkpoint blockade (ICB) therapy, cancer vaccine therapy and so on.6–10 However, in spite of the great success achieved to date in not only clinical treatment but also basic research, cancer immunotherapy still faces many huge challenges, like low response rates, severe treatment-associated adverse effects, acquired immunological tolerance and so forth.11 Furthermore, the complicated cancer-immunity cycle process and the immunosuppressive tumor microenvironment can further hinder the course of immunotherapy.12 Encouragingly, the development of materials science and nanotechnology offers new opportunities and prospects for cancer immunotherapy.13–17 To date, multifarious nanomaterials have been fabricated to boost anti-tumor immunotherapy through various mechanisms, which include three major strategies: nanomaterial-mediated combination therapy, adjustment of the immunosuppressive tumor microenvironment and construction of nanovaccines.18–22
In the past two decades, increasing attention has been paid to manganese oxide nanomaterials (MONs) and their derivatives in biomedical applications, including bioimaging, biosensing, drug delivery and tumor therapy due to their excellent biosecurity and unique physical/chemical properties.23–27 MONs are able to catalyze H+/hydrogen peroxide (H2O2) to oxygen (O2) and Mn2+, and oxidize glutathione (GSH) into oxidized glutathione (GSSH).28–30 As is well known, the tumor microenvironment (TME) characteristically displays hypoxia, mild acidity, and GSH/H2O2 overproduction.31,32 Therefore, MONs as ideal TME-responsive biomaterials were designed to enhance the therapeutic efficiency by adjusting the immunosuppressive tumor microenvironment. For example, by overcoming tumor hypoxia, MONs can dramatically promote the tumor ablation in photodynamic therapy (PDT),33 sonodynamic therapy (SDT),34 and radiotherapy (RT).35 In addition, it has been proved that MONs can be used directly for photothermal therapy (PTT),36 ferroptosis,37 chemodynamic therapy (CDT),38 immunotherapy,39etc. Overall, manganese oxide-based nanomaterials hold great promise and have made huge progress in biomedical applications, particularly in tumor therapy. Some recent reviews by different groups including ours have outlined the progress in synthesis, properties, imaging, biodetection and therapeutic applications of MONs.40–43 However, a comprehensive and specialized review on MONs for cancer immunotherapy has not been reported yet.
Inspired by the significant headway and great prospects of MONs in immunotherapy, herein, this review aims to provide a comprehensive overview of MONs and their derivatives for cancer immunotherapy. On the basis of different mechanisms to boost immunotherapy, major highlighted topics are presented, covering adjusting an immunosuppressive TME by generating O2 (like O2-sensitized PDT, programmed cell death ligand-1 (PD-L1) expression downregulation, reprogramming tumor-associated macrophages (TAMs), and restraining tumor angiogenesis and lactic acid exhaustion), inducing immunogenic cell death (ICD), PTT induction, activating the stimulator of interferon gene (STING) pathway and immunoadjuvants for nanovaccines (Scheme 1 and Table 1). Finally, the current challenges and future directions of MONs for immunotherapy are further discussed. We believe that this review will bring more inspirations to not only cancer immunotherapy but also the further application and conversion of manganese oxide-related nanoplatforms.
![image file: d1tb01001h-s1.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-s1.gif) |
| Scheme 1 Schematic illustration of boosting cancer immunotherapy via manganese oxide nanomaterials by various mechanisms. Remarks: glutathione (GSH), oxidized glutathione (GSSH), photothermal therapy (PTT), photodynamic therapy (PDT), hypoxia inducible factor-1α (HIF-1α), tumor-associated macrophages (TAM), programmed cell death ligand-1 (PD-L1), immunogenic cell death (ICD), chemodynamic therapy (CDT), and stimulator of interferon genes (STING). | |
Table 1 Comparisons of different mechanisms of MONs for cancer immunotherapy
Category |
Mechanisms |
Materials |
Main functions |
Cells |
Ref. |
Remarks: tumor microenvironment (TME), photodynamic therapy (PDT), immunogenic cell death (ICD), photothermal therapy (PTT), stimulator of interferon genes (STING), tumor associated macrophages (TAMs), bovine serum albumin (BSA), polyethylene glycol (PEG), lipid-poly(lactic-co-glycolic) acid (PLGA), red blood cell membrane (mRBC), hypoxia inducible factor-1α (HIF-1α), cancer cell membrane (CM). |
Adjusting TME by producing O2 |
O2-Sensitized PDT |
Au@MnO2 |
Improving PDT efficiency to promote PDT-activated immune responses |
4T1 |
44
|
PD-L1 expression downregulation |
BSA-MnO2-IPI549 |
Reducing HIF-1α expression, which can selectively upregulate PD-L1 |
4T1 |
45
|
Reprogramming TAMs |
PEG-modified Ce6/DOX-loaded hollow MnO2 |
Improving PDT efficiency and inducing TAM polarization from M2 to M1 |
4T1 |
46
|
Restraining tumor angiogenesis |
MnO2@PLGA-sorafenib |
Inducing TAM polarization from M2 to M1 and promoting sorafenib-induced decrease in tumor vascularization |
Murine HCC |
47
|
Lactic acid exhaustion |
mRBC-coated lactate oxidase/glycolysis inhibitor-loaded hollow MnO2 |
Promoting lactate oxidase-mediated oxidation reaction of lactic acid |
B16F10 |
48
|
ICD induction |
CDT and ferroptosis-induced ICD |
MnOx |
Mn2+-mediated CDT via Fenton-like reactions and GSH-depleting ferroptosis |
4T1 |
49
|
|
ICD under nutrient-deprived conditions |
MnO2 |
Might elicit the autophagy machinery that in turn contributes to induction of ICD |
4T1 |
50
|
PTT activation |
PTT induces ICD |
MnO2-based nanogels |
As a photothermal agent to achieve PTT-triggered antigens release |
4T1 |
39
|
Activating STING pathway |
Mn2+ Activates STING pathway |
CM-coated MnO2 |
Increase the pH value of TME, alleviate tumor hypoxia and activate STING pathway |
B16F10 |
51
|
Immunoadjuvant |
Adjuvant effect |
MnOx |
As an immunoadjuvant for antigen delivery |
4T1 |
49
|
2. Adjusting immunosuppressive TME by generating O2
The outcome of immunotherapy is greatly limited to immunosuppressive TME. For instance, hypoxia, a characteristic feature of solid tumors, can bring about a series of adverse consequences on antitumor immune response, including upregulations of PD-L1 and tumor invasion-related signaling molecules like vascular endothelial growth factor (VEGF), which are mainly involved in angiogenesis and metastasis.45,52 Therefore, it is very necessary and important to modify immunosuppressive conditions and reshape the tumor immune microenvironment. As an excellent endogenous O2 donor by reacting with H2O2/H+, manganese oxide-based nanosystems show superior ability for adjusting immunosuppressive TME by overcoming tumor hypoxia.
2.1 O2-Sensitized PDT
Classical PDT, a noninvasive therapy modality based on the photochemical reactions of photosensitizers (PSs) to generate cytotoxic intracellular reactive oxygen species (ROS), is an effective cancer therapeutic strategy.53,54 In particular, it has been demonstrated that PDT could not only kill cancer cells directly, but also elicit antitumor immune responses via release of tumor-associated antigens (TAAs), also called ICD.55–58 However, tumor hypoxia greatly limits the efficiency of O2-dependent PDT.59 MONs can tremendously enhance PDT efficiency by reacting with H2O2/H+ to produce O2, and thus promote antitumor immunity.
A representative example was presented by the Cai group, in which they prepared core–shell gold nanocage@manganese dioxide (AuNC@MnO2, AM) nanoparticles as tumor microenvironment-responsive O2 producers and near-infrared (NIR)-triggered ROS generators for O2-sensitized immunogenic PDT (Fig. 1a and b).44 As shown in Fig. 1c, compared with other groups, enhanced ROS contents were observed in the AM + laser group, indicating that O2 produced by MnO2 can promote PDT. Next, the markers of ICD as a cornerstone of therapy-induced antitumor immunity were further tested and the results reveal that the AM + laser group can induce the most conspicuous calreticulin (CRT) exposure and adenosine triphosphate (ATP)/high mobility group protein B1 (HMGB1) release (Fig. 1d–f). The elevated immune response was examined by dendritic cells (DCs) maturity and interleukin 12 (IL-12) secretion using co-cultivation of mouse bone marrow-derived dendritic cells (BMDCs) and 4T1 cells (Fig. 1g and h). Next, in vivo study confirmed that AM under 808 nm laser irradiation not only ablated the primary tumor directly but also inhibited tumor metastasis and recurrence. In addition, the authors also found that AM can relieve tumor hypoxia by in situ oxygenation to remodel the immunosuppressive TME by decreasing regulatory T cell (Treg) expression. Similarly, other groups also reported that enhanced antitumor immunity can be achieved by O2-sensitized PDT.60–66
![image file: d1tb01001h-f1.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f1.gif) |
| Fig. 1 (a) Preparation procedure of core–shell gold nanocage@manganese dioxide (AuNC@MnO2, AM) and its applications in acid/H2O2-responsive oxygen-boosted PDT. (b) The therapeutic mechanism of AM for multimodal imaging-guided oxygen-boosted PDT. (c) ROS detection in 4T1 cells after treatment with AM and 808 nm laser irradiation (0.8 W cm−2, 3 min) by confocal microscopy. (d) Immunofluorescence microscopy of CRT expression on 4T1 cell surface after treatment with AM and laser irradiation. (e) Released ATP in the supernatant. (f) Released HMGB1 in the supernatant. (g) The expression of CD83 and CD86 of mature DC stimulated by ICD signal molecules. (h) Production of IL-12 in the culture supernatant. The asterisks indicate that differences between PBS and other treatments are statistically significant. **p < 0.01, ***p < 0.001. Reproduced with permission.44 Copyright 2018, Elsevier. | |
2.2 PD-L1 expression downregulation
Hypoxia-inducible factor-1α (HIF-1α) selectively up-regulates PD-L1 by binding to the hypoxia response elements (HRE) in the PD-L1 proximal promoter, which dampens the antitumor immune response.67,68 Hence, MONs as an O2 supplier can reduce PD-L1 expression by overcoming tumor hypoxia to boost immunotherapy. Based on this, Yu and co-workers prepared a multifunctional nanoregulator incorporating MnO2 particles and small molecular IPI549 (BMI) to reshape the tumor immune microenvironment (TIME) as displayed in Fig. 2.45 Here, IPI549, as a small molecular gamma isoform of phosphoinositide 3-kinase (PI3Kγ) inhibitor, can switch macrophages from the immunosuppressive M2-like phenotype to the pro-inflammatory M1-like state. Due to the synergistic effect of hypoxia alleviation via oxygen-generating reduction of MnO2 and PI3Kγ inhibition, the nanoplatform achieved concurrent downregulation of PD-L1 expression and polarization of tumor associated macrophages (TAMs), suggesting effective tumor immunotherapy. Fig. 2c–e show that MnO2-embedded nanoregulators resulted in a significant down-regulation of HIF-1α and PD-L1 expressions via immunofluorescence staining and western blotting assay.
![image file: d1tb01001h-f2.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f2.gif) |
| Fig. 2 (a) A scheme showing the pH/H2O2 responsiveness of bovine serum albumin (BSA)-MnO2-IPI549 (BMI). (b) Schematic illustration of reshaping the tumor immune microenvironment (TIME) by a pluripotent nanoregulator. (c) Immunofluorescence analysis of HIF-1α and PD-L1 expressions of 4T1 cells after incubation for 24 h with different formulations (200 μg mL−1) under hypoxia and normoxia conditions, respectively. (d) Western blot analysis of PD-L1 protein in 4T1 tumors collected from mice on the 18 d during treatment. (e) Immunofluorescence assays displaying HIF-1α sections from mice after drug withdrawal. Reproduced with permission.45 Copyright 2019, Wiley-VCH. | |
The residual HIF-1α will further dimerize with HIF-1β to form HIF-1 and activate tumor invasion-related signaling molecules like VEGF and matrix metalloproteinase 9 (MMP-9). The Yuan group demonstrated that the expression of tumor invasion-related signaling molecules (VEGF and MMP-9) was obviously decreased under down-regulation of HIF-1 by the introduction of MnO2 nanoparticles, which helps to reduce the risk of metastasis.52
2.3 Reprogramming TAMs
Normally, macrophages can be divided into two subtypes, the classically activated pro-inflammatory (M1) phenotype (attacking invaders) and the alternatively activated anti-inflammatory (M2) phenotype (healing damages).69 It has been revealed that M2 phenotype TAMs support tumor progression via secretion of pro-tumor cytokines such as IL-10, and thereby promote tissue repair and tumor recurrence including angiogenesis, matrix remodeling, and immunosuppression.70,71 In contrast, M1 phenotype TAMs exhibit classic antitumor activity by producing multiple cytotoxic cytokines like tumor necrosis factor alpha (TNF-α) and IL-6.72,73 Another strategy of adjusting immunosuppressive TME by MONs and their derivatives is to reprogram TAMs via the transformation of the M2 to the M1 phenotype.69 A typical example developed by the Liu group showed that polyethylene glycol (PEG)-modified chlorine e6 (Ce6)/doxorubicin (DOX)-loaded hollow manganese dioxide (H-MnO2-PEG/C&D) was prepared for combination therapy favoring antitumor immune responses (Fig. 3a and b).46 Here, the tumor hypoxia was relieved by MnO2-mediated decomposition of endogenous H2O2 inside tumors, which not only improved the efficacy of chemo-PDT, but also reversed the immunosuppressive TME to favor anti-tumor immunity post treatment. Under an oxygen atmosphere and 660 nm light irradiation, both free Ce6 and Ce6-loaded MnO2 nanoparticles exhibited high cytotoxicity. However, the phototoxicity of free Ce6 was found to be significantly lower, while the cell killing efficiency of Ce6-loaded MnO2 nanoparticles remained at high levels under hypoxic conditions. What's more, as displayed in Fig. 3c, compared with the untreated group, tumors in mice with i.v. injection of H-MnO2-PEG/C&D plus light irradiation showed markedly elevated macrophage infiltration within tumors from 0.8% to 8%, together with reduced population of M2 phenotype TAMs from 40% to 9.5% among all the TAMs. Furthermore, in the H-MnO2-PEG/C&D-injected mice under light exposure, the secretion of IL-10 in the supernatant of tumor lysates also decreased by 3.77 times (Fig. 3d); however, the content of IL-12 in tumors presented a significant increase (Fig. 3e), both suggesting remarkable M2 to M1 polarization within tumors.
![image file: d1tb01001h-f3.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f3.gif) |
| Fig. 3 (a) The proposed mechanism of anti-tumor immune responses induced by polyethylene glycol (PEG)-modified chlorine e6 (Ce6)/doxorubicin (DOX)-loaded hollow manganese dioxide (H-MnO2-PEG/C&D) in combination with anti-PD-L1 therapy. (b) A scheme indicating the step-by-step synthesis of H-MnO2-PEG nanoparticles and the subsequent dual-drug loading. (c) Macrophage infiltration and polarization within tumors post various treatments. CD11b+CD206+ cells were defined as M2 phenotype macrophages (six mice per group). The total number of macrophages infiltrated in tumors markedly increased after the combined chemo-PDT, which also resulted in polarization of M2 phenotype TAM towards M1 TAM. The levels of IL-10 (d) and IL-12p40 (e) in the supernatant of tumors post various treatments. Reproduced with permission.46 Copyright 2017, Springer Nature. | |
2.4 Restraining tumor angiogenesis
The formation of blood vessels that supply nutrients and oxygen is very important for solid tumor growth and progression. Therefore, based on the vital function of abnormal vessels in the TME, anti-angiogenic therapy has become a widely studied therapeutic strategy.74–76 Sorafenib, as an anti-angiogenic agent, has been approved by the US Food and Drug Administration (FDA). However, hypoxia can result in severe resistance to sorafenib.77 To overcome this challenge, Chang et al. prepared NanoMnSor, which is composed of a MnO2 core and a lipid-poly(lactic-co-glycolic) acid (PLGA) shell loaded with sorafenib (Fig. 4).47 The authors confirmed that this nanomaterial is not only able to promote macrophage polarization toward the immunostimulatory M1 phenotype, but also leads to sorafenib-induced decrease in tumor vascularization by generating abundant O2. Additionally, the NanoMnSor treatment can reverse hypoxia-induced cell invasion and epithelial-to-mesenchymal transition (EMT), and thus significantly inhibit tumor metastasis. In brief, this study demonstrates the potential of oxygen-generating NanoMnSor, efficiently boosting anti-angiogenic therapy and immune responses. A similar result was also reported by He et al. and bovine serum albumin (BSA)-modified sorafenib/Ce6-co-loaded MnO2 nanocomposites were obtained to relieve immunosuppression during long-term anti-angiogenesis therapy.62
![image file: d1tb01001h-f4.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f4.gif) |
| Fig. 4 Schematic representation of the mechanism by which NanoMnSor can serve as a theranostic anticancer agent. Oxygen generated from NanoMnSor, which is composed of a MnO2 core and a lipid-poly(lactic-co-glycolic) acid (PLGA) shell loaded with sorafenib, alleviates tumor hypoxia and modulates the TME. (1) NanoMnSor treatment overcomes hypoxia-driven resistance to sorafenib and reduces cancer cell proliferation in hepatocellular carcinoma (HCC). (2) NanoMnSor ameliorates the immunosuppressive TME by reducing the hypoxia-induced tumor infiltration of TAMs. (3) NanoMnSor suppresses metastasis in HCC by attenuating hypoxia-induced epithelial-to-mesenchymal transition (EMT). (4) NanoMnSor treatment enhances antiangiogenic effect of sorafenib via hypoxia alleviation. (5) NanoMnSor potentially serves as a magnetic resonance imaging (MRI) contrast agent (CA). Reproduced with permission.47 Copyright 2020, American Chemical Society. | |
2.5 Lactic acid exhaustion
Lactic acid, the most ubiquitous component of TME, is ceaselessly produced by the aerobic glycolysis of tumor cells for energy production. It has been confirmed that the mass of lactic acid is adverse to antitumor immunotherapy.78–80 To this end, the Zhang group proposed an innovative intra/extracellular lactic acid exhaustion strategy for synergistic antitumor metabolic therapy and ICB therapy.48 Firstly, red blood cell membrane (mRBC)-encapsulated 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO, glycolysis inhibitor)/lactate oxidase (LOX)-co-loaded hollow MnO2 (HMnO2) nanoparticles (denoted as PMLR) were synthesized as presented in Fig. 5a. In this work, LOX was introduced to catalyze the oxidation reaction of lactic acid with O2, and the byproduct could be further catalyzed by HMnO2 to generate O2 for lactic acid oxidation (Fig. 5b–d). At the same time, the intracellular nanosystem can further release the glycolysis inhibitor to interdict the source of lactic acid and ATP supply for antitumor metabolic therapy. The data showed that the PMLR nanosystem could ceaselessly remove lactic acid, and then bring about an immunocompetent TME and notably enhance the efficiency of anti-PD-L1 therapy.
![image file: d1tb01001h-f5.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f5.gif) |
| Fig. 5 Schematic illustration of the intra/extracellular lactic acid exhaustion process of the PMLR nanosystem. (a) Preparation steps of the PMLR nanosystem. (b) The mRBC-camouflaged nanosystem can avoid the phagocytosis of macrophages through the CD47-mediated “don't eat me” signal. (c) PMLR nanosystem releases 3PO to inhibit the glycolysis of tumor cells and catalyzes the decomposition of endogenous H2O2 to sensitize the 3PO. This process cuts off the source of ATP and lactic acid. (d) Cascade catalysis process of the PMLR nanosystem. The PMLR nanosystem catalyzes the oxidation process of extracellular lactic acid to generate pyruvate and H2O2, the latter of which can be further converted into O2 to accelerate the lactic acid oxidation process. Reproduced with permission.48 Copyright 2019, Wiley-VCH. | |
3. ICD induction
The dying tumor cells after drug treatment can generate damage-associated molecular patterns (DAMPs), including CRT, heat shock proteins (HSP70 and HSP90), HMGB1, and ATP, which can further stimulate the engulfment of dying tumor cells by immature DCs, resulting in DC maturation.81–84 This functionally peculiar type of cell death is termed “ICD”.85,86 As mentioned above, manganese oxide-based nanoplatforms play a subsidiary role in assisting PDT-induced ICD by creating a favorable microenvironment. However, the intrinsic immunogenicity and ICD induction of MONs are still unclear. Until recently, as far as we know, our group first demonstrated that MONs can intrinsically induce ICD via CDT and ferroptosis inductions due to highly efficient ˙OH generation and GSH depletion capabilities.49 After that, the Yu group also found that MnO2 nanoflowers (MNFs) can efficiently induce ICD in cancer cells under nutrient-deprived conditions (Fig. 6a and b).50 The two studies help to break the stereotype of the subsidiary role of MONs in cancer immunotherapy. As exhibited in Fig. 6c and d, compared with the groups treated with full media, amino-acid-deprived (AA−) media and MNFs + full media, MNFs + AA− media-incubated 4T1 cells showed significantly increased exposure level of ecto-CRT and ATP/HMGB1 release acting as “eat me” signals and “find me” signals, respectively. Next, the underlying mechanism of the MNF-mediated ICD under nutrient-deprived conditions was further studied and the authors explained that MNFs in nutrient deficiency might elicit the autophagy machinery that in turn contributes to the induction of ICD. Based on these findings, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a drug that specifically targets endothelial cells and damages the tumor vasculature system (blood vessels) to cut off nutrient supply, was chosen for synergistic cancer starvation-immunotherapy in combination with MNFs.
![image file: d1tb01001h-f6.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f6.gif) |
| Fig. 6 (a) Schematic illustration of MnO2 nanoflowers (MNFs) for nutrient-dependent immunogenic cell death (ICD). (b) Transmission electron microscopy (TEM) image of MnO2 nanoflowers. (c) Confocal laser scanning microscopy (CLSM) image of the surface exposure of ecto-CRT on 4T1 cells. 4T1 cells were cultured in full media, amino-acid-deprived (AA−) media, MNFs + full media, and MNFs + AA− media, respectively. (d and e) Secretion of ATP and HMGB-1 in the cell culture media. Reproduced with permission.50 Copyright 2020, Wiley-VCH. | |
4. PTT activation
It has been proved that PTT facilitates the in situ release of tumor-derived protein antigens (TDPAs) and other immune stimulating substances by eliciting the immunogenic death of autologous tumor cells, which can trigger a robust immune response.87–90 MnO2 nanomaterials with intense absorption in the near infrared region possess photothermal conversion capability and can be used for PTT.36,91 Hence, MONs are capable of activating antitumor immunity by releasing autologous antigens via PTT induction. A recent example reported by Fan et al. reveals this process well.39 As shown in Fig. 7a, thermosensitive poly(N-isopropylacrylamideco-dopamine methacrylamide) (PND) nanogels were synthesized firstly and then MnO2 nanoparticles (MnO2 NPs) were formed in the network of the PND nanogels (MnO2@PND) via an in situ mineralization process. The photothermal effect of MnO2 NPs induced ICD to release mass autologous TDPAs under near-infrared irradiation. At the same time, an injectable hydrogel like an “antigen reservoir” can capture the antigens generated by PTT due to the existence of catechol groups, and thus achieve lasting anti-tumor immune response (Fig. 7b). Under continuous 808 nm laser irradiation (1.0 W cm−2) for 10 min, the temperature changes (ΔT) of PBS and PND dispersions were smaller than 8 °C, while the ΔT of the MnO2@PND dispersion (100 mg mL−1) achieved was up to 34 °C, suggesting that the photothermal effects were originated from MnO2 NPs. The photothermal conversion efficiency (η) of MnO2@PND was determined to be 33.2%. Furthermore, under 808 nm laser irradiation, MnO2@PND-treated cells showed the highest level of CRT exposure and the highest release of HMGB1. In vivo study demonstrated that the obtained MnO2@PND nanogels eliminated the primary tumors completely and effectively suppressed distal/rechallenged tumors, showing great potential in PTT-induced immunotherapy.
![image file: d1tb01001h-f7.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f7.gif) |
| Fig. 7 (a) Schematic showing the preparation of the poly(N-isopropylacrylamide-co-dopamine methacrylamide) (PND) and MnO2@PND nanogels. (b) Schematic illustration of the mechanism of “antigen reservoir” formation and the anti-tumor immune response to inhibit the growth of primary tumor, distal tumor, and rechallenged tumor. Reproduced with permission.39 Copyright 2021, Wiley-VCH. | |
5. Activating the STING pathway
The cyclic GMP-AMP synthase (cGAS)/STING pathway, as an endogenous mechanism in an innate immune system, can activate antitumor immune responses through the spontaneous secretion of type I interferon (IFN-I) and pro-inflammatory cytokines.92,93 Recently, increasing attention has been paid to STING-mediated stimulation of the innate immune system because it is very important for spontaneous induction of antitumour T-cell immunity.94,95 Meanwhile, it should be noted that Mn2+ ions in the cytoplasm as an alarmin and an activator in innate immune system, have potential to activate intracellular STING pathway.96,97 Inspired by this, Hou et al. constructed doxorubicin (DOX)-loaded and phospholipid (PL)-coated amorphous porous manganese phosphate (APMP) nanoparticles (PL/APMP-DOX NPs).98 After systemic administration, this nanomaterials release DOX for inducing DNA damage and Mn2+ to augment cGAS/STING activity, and thus promote DC maturation, cytotoxic T lymphocyte (CTL) induction, natural killer cell (NK) recruitment, and type I IFN/TNF-α expressions, indicating that this innate immunity nanoactivator has the potential to amplify antitumor immunotherapeutic efficacy. Using a similar principle, Sun and co-workers developed a straight and versatile strategy for in situ STING-activating vaccination (ISSAV) by converting a primary tumor towards a therapeutic STING vaccine.51 For this purpose, they prepared cancer cell membrane (CM)-encapsulated MnO2 NPs and immobilized photothermal agent (DiR) (CMM-DiR). As presented in Fig. 8a–d, on the one hand, CMM-DiR induced the exposure of numerous TAAs by hyperthermia, thus transforming the primary tumors into TAAs. On the other hand, CMM-DiR realized burst release of Mn2+ to activate the STING pathway and build a therapeutic STING vaccine in conjunction with TAAs. Accordingly, the primary tumor possessed the dual functions as adequate antigens and STING agonist depots. Additionally, the degradation of MnO2 also generated numerous O2 and increased the pH value of TME, which was more conducive to the infiltration of the T lymphocyte. In short, the ISSAV proposed by this paper brings inspiration for cancer vaccinations and personalized immunotherapy.
![image file: d1tb01001h-f8.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f8.gif) |
| Fig. 8 Schematic of the in situ STING-activating vaccination (ISSAV) strategy achieved using a biomimetic nanoplatform (CMM-DiR). (a) A schematic illustration of how the biomimetic nanoplatform coverts immunosuppressive tumors towards the in situ STING-activating vaccine and elicits immune response. (b and c) The details of how ISSAV strategy works. Following intravenous administration, CMM-DiR was accumulated in the tumor. Then, the nanoplatform could be degraded quickly into Mn2+ and CM-DiR in TME, along with the production of O2 and the consumption of H+. The remaining nanoplatform (CM-DiR) is taken up by the tumor cells through the homotypic adhesion property. Next, under laser irradiation, due to hyperthermia, tumor cells release a large number of TAAs, thus transforming the primary tumor into a STING-activating vaccine. This in situ STING vaccine can promote DC maturation through STING activation and MHC presentation. Finally, the mature DCs induce the priming of the T lymphocyte for combating incurable tumors (metastatic tumors, and multinodular and tumor recurrent tumors). (d) Composition of the nanoplatform (CMM-DiR) and the function of each component. Reproduced with permission.51 Copyright 2021, Elsevier. | |
6. Immunoadjuvant
Immunoadjuvant refers to a substance which is injected into the body prior to the antigen or after mixing with antigen, which can non-specifically change or enhance the body's specific immune response to the antigen, and thus plays an adjuvant role.99–101 Alum adjuvant, as the most widely used immunoadjuvant, has been applied in dozens of vaccine products.102,103 However, the long-term retention effect and possible toxicity of aluminum adjuvants limit their future applications. Finding appropriate and safe immunoadjuvants has always been a major challenge. Inspired by biodegradable properties and the biosafety of MONs, our group first reported that MnOx nanospikes (NSs) can serve as immunoadjuvants for cancer nanovaccine-based immunotherapy (Fig. 9a–d).49 Compared with traditional immunoadjuvants, using MnOx as a immunoadjuvant has the following merits: (a) MnOx is biodegradable, avoiding in vivo long-term retention; (b) manganese is one of the essential elements in the human body and MnOx possesses good biosecurity; (c) MnOx can modulate immunosuppressive TME by the production of O2 and the consumption of H+; (d) MnOx NSs with large mesopores structures show high antigen loading capacities; (e) MnOx can intrinsically induce ICD via CDT and ferroptosis induction, triggering dying tumor cells to generate DAMPs; (f) MnOx NSs display TME-responsive magnetic resonance (MR)/photoacoustic (PA) dual-mode imaging capacities. Moreover, MnOx NSs prepared by a fast aqueous phase synthesis method at room temperature avoids complicated nanomaterial modulation, which is beneficial for future applications. Next, in vivo tests further testified that the corporate administration of adjuvants and antigens showed the best DC maturity, T-cell activation, cytokine secretion and tumor growth inhibition in comparison with adjuvants and antigens alone, indicating that MnOx can act as an immunoadjuvant to enhance in vivo specific immune responses. Very recently, Chen's group also reported a new nanovaccine comprising the Receptor-Binding Domain (RBD) of the spike protein and the manganese nanoadjuvant (MnARK) for inducing potent protective immunity against the novel coronavirus.104 They found that even at a 5-fold lower antigen dose and with fewer injections, mice immunized with the MnARK vaccine displayed stronger neutralizing abilities against the infection of the pseudovirus (∼270-fold) and live coronavirus (>8-fold) in vitro than that of Alum-adsorbed RBD vaccine (Alu-RBD). In brief, the above two works reveal that MONs as new-style immunoadjuvants are feasible and possess broad prospects in vaccines.
![image file: d1tb01001h-f9.tif](/image/article/2021/TB/d1tb01001h/d1tb01001h-f9.gif) |
| Fig. 9 (a) Illustration of MnOx–OVA/tumor cell fragment (TF) nanovaccines for MR/PA dual-mode imaging-induced cancer immunotherapy. (b) TEM and (c) scanning TEM (STEM) images of MnOx NSs. (d) Elemental mapping of MnOx–OVA. Reproduced with permission.49 Copyright 2020, Wiley-VCH. | |
7. Conclusions and outlook
In this review, we have summarized the recent advances in MONs and their derivatives for cancer immunotherapy. According to the different mechanisms for boosting immunotherapy, major highlighted topics are introduced, such as the adjustment of an immunosuppressive TME by generating O2 (including O2-sensitized PDT, PD-L1 expression downregulation, reprogramming tumor-associated macrophages, restraining tumor angiogenesis and lactic acid exhaustion), ICD induction, PTT activation, activation of the STING pathway and immunoadjuvants for nanovaccines.
In short, MON-based nanoplatforms like an all-rounder are able to dramatically elicit anti-tumor immune responses in multiple ways, which have the most obvious advantages over other nanomaterials in cancer immunotherapy. Hence MONs can be designed to promote immune responses and therapeutic outcomes simultaneously through several mechanisms. For complex immune systems and TME, it is very important for obtaining an ideal treatment effect. Additionally, we should also pay more attention to the latest discoveries about MONs in immunotherapy, including activation of the STING pathway and serving as immunoadjuvants for nanovaccines. Do manganese adjuvants become the next generation of adjuvants like classical aluminium adjuvants? It may be an important one of the future research directions. Furthermore, some other challenges still persist and remain to be solved, like large-scale production, potential toxicity analysis, in-depth study of MON-related immune mechanisms and so on. It is very urgent and highly desired that multidisciplinary cooperation will promote a more rapid clinical translation of MONs. We hope that this review will provide a holistic understanding about MONs and their application in cancer immunotherapy, and thus pave the way to the bench to bedside translation in the future.
Conflicts of interest
The authors declare no conflict of interest.
Acknowledgements
This work is financially supported by the Science and Technology Cooperation Project between Chinese and Australian Governments (2017YFE0132300), the National Natural Science Foundation of China (Grant No. NSFC 51720105015, 51929201, 51922097, 51772124 and 51872282), the Key Research Program of Frontier Sciences, CAS (YZDY-SSW-JSC018), the Postdoctoral Innovative Talents Support Program (BX2021360) and the Youth Innovation Promotion Association of CAS (Grant No. 2017273).
References
- Y. Min, K. C. Roche, S. Tian, M. J. Eblan, K. P. McKinnon, J. M. Caster, S. Chai, L. E. Herring, L. Zhang, T. Zhang, J. M. DeSimone, J. E. Tepper, B. G. Vincent, J. S. Serody and A. Z. Wang, Nat. Nanotechnol., 2017, 12, 877–882 CrossRef CAS PubMed
.
- M. Luo, H. Wang, Z. Wang, H. Cai, Z. Lu, Y. Li, M. Du, G. Huang, C. Wang, X. Chen, M. R. Porembka, J. Lea, A. E. Frankel, Y.-X. Fu, Z. J. Chen and J. Gao, Nat. Nanotechnol., 2017, 12, 648–654 CrossRef CAS PubMed
.
- I. Mellman, G. Coukos and G. Dranoff, Nature, 2011, 480, 480–489 CrossRef CAS PubMed
.
- S. A. Rosenberg, J. C. Yang and N. P. Restifo, Nat. Med., 2004, 10, 909–915 CrossRef CAS PubMed
.
- T. N. Schumacher and R. D. Schreiber, Science, 2015, 348, 69–74 CrossRef CAS PubMed
.
- Q. Chen, M. Chen and Z. Liu, Chem. Soc. Rev., 2019, 48, 5506–5526 RSC
.
- D. B. Keskin, A. J. Anandappa, J. Sun, I. Tirosh, N. D. Mathewson, S. Li, G. Oliveira, A. Giobbie-Hurder, K. Felt, E. Gjini, S. A. Shukla, Z. Hu, L. Li, P. M. Le, R. L. Allesoe, A. R. Richman, M. S. Kowalczyk, S. Abdelrahman, J. E. Geduldig, S. Charbonneau, K. Pelton, J. B. Iorgulescu, L. Elagina, W. Zhang, O. Olive, C. McCluskey, L. R. Olsen, J. Stevens, W. J. Lane, A. M. Salazar, H. Daley, P. Y. Wen, E. A. Chiocca, M. Harden, N. J. Lennon, S. Gabriel, G. Getz, E. S. Lander, A. Regev, J. Ritz, D. Neuberg, S. J. Rodig, K. L. Ligon, M. L. Suva, K. W. Wucherpfennig, N. Hacohen, E. F. Fritsch, K. J. Livak, P. A. Ott, C. J. Wu and D. A. Reardon, Nature, 2019, 565, 234–239 CrossRef CAS PubMed
.
- U. Sahin, P. Oehm, E. Derhovanessian, R. A. Jabulowsky, M. Vormehr, M. Gold, D. Maurus, D. Schwarck-Kokarakis, A. N. Kuhn, T. Omokoko, L. M. Kranz, M. Diken, S. Kreiter, H. Haas, S. Attig, R. Rae, K. Cuk, A. Kemmer-Brueck, A. Breitkreuz, C. Tolliver, J. Caspar, J. Quinkhardt, L. Hebich, M. Stein, A. Hohberger, I. Vogler, I. Liebig, S. Renken, J. Sikorski, M. Leierer, V. Mueller, H. Mitzel-Rink, M. Miederer, C. Huber, S. Grabbe, J. Utikal, A. Pinter, R. Kaufmann, J. C. Hassel, C. Loquai and O. Tuereci, Nature, 2020, 585, 107–112 CrossRef CAS PubMed
.
- X. Han, H. Li, D. Zhou, Z. Chen and Z. Gu, Acc. Chem. Res., 2020, 53, 2521–2533 CrossRef CAS PubMed
.
- D. M. Pardoll, Nat. Rev. Cancer, 2012, 12, 252–264 CrossRef CAS PubMed
.
- C. Zhang and K. Pu, Chem. Soc. Rev., 2020, 49, 4234–4253 RSC
.
- S. Yan, Z. Luo, Z. Li, Y. Wang, J. Tao, C. Gong and X. Liu, Angew. Chem., Int. Ed., 2020, 59, 17332–17343 CrossRef CAS PubMed
.
- Q. Sun, M. Barz, B. G. De Geest, M. Diken, W. E. Hennink, F. Kiessling, T. Lammers and Y. Shi, Chem. Soc. Rev., 2019, 48, 351–381 RSC
.
- W. Sang, Z. Zhang, Y. Dai and X. Chen, Chem. Soc. Rev., 2019, 48, 3771–3810 RSC
.
- W. Li, Z. Liu, F. Fontana, Y. Ding, D. Liu, J. T. Hirvonen and H. A. Santos, Adv. Mater., 2018, 30, 1703740 CrossRef PubMed
.
- H. Phuengkham, L. Ren, I. W. Shin and Y. T. Lim, Adv. Mater., 2019, 31, 1803322 CrossRef PubMed
.
- W. Song, S. N. Musetti and L. Huang, Biomaterials, 2017, 148, 16–30 CrossRef CAS PubMed
.
- Y. Shi and T. Lammers, Acc. Chem. Res., 2019, 52, 1543–1554 CrossRef CAS PubMed
.
- M. E. Aikins, C. Xu and J. J. Moon, Acc. Chem. Res., 2020, 53, 2094–2105 CrossRef CAS PubMed
.
- H. Cabral, H. Kinoh and K. Kataoka, Acc. Chem. Res., 2020, 53, 2765–2776 CrossRef CAS PubMed
.
- A. S. Cheung and D. J. Mooney, Nano Today, 2015, 10, 511–531 CrossRef CAS PubMed
.
- R. H. Fang, A. V. Kroll and L. Zhang, Small, 2015, 11, 5483–5496 CrossRef CAS PubMed
.
- Z. Zhao, H. Fan, G. Zhou, H. Bai, H. Liang, R. Wang, X. Zhang and W. Tan, J. Am. Chem. Soc., 2014, 136, 11220–11223 CrossRef CAS PubMed
.
- Y. Chen, D. Ye, M. Wu, H. Chen, L. Zhang, J. Shi and L. Wang, Adv. Mater., 2014, 26, 7019–7026 CrossRef CAS PubMed
.
- J. Liu, L. Meng, Z. Fei, P. J. Dyson, X. Jing and X. Liu, Biosens. Bioelectron., 2017, 90, 69–74 CrossRef CAS PubMed
.
- R. Deng, X. Xie, M. Vendrell, Y.-T. Chang and X. Liu, J. Am. Chem. Soc., 2011, 133, 20168–20171 CrossRef CAS PubMed
.
- M. Song, T. Liu, C. Shi, X. Zhang and X. Chen, ACS Nano, 2016, 10, 633–647 CrossRef CAS PubMed
.
- W. Fan, W. Bu, B. Shen, Q. He, Z. Cui, Y. Liu, X. Zheng, K. Zhao and J. Shi, Adv. Mater., 2015, 27, 4155–4161 CrossRef CAS PubMed
.
- H. Fan, G. Yan, Z. Zhao, X. Hu, W. Zhang, H. Liu, X. Fu, T. Fu, X.-B. Zhang and W. Tan, Angew. Chem., Int. Ed., 2016, 55, 5477–5482 CrossRef CAS PubMed
.
- B. Ding, S. Shao, F. Jiang, P. Dang, C. Sun, S. Huang, P. A. Ma, D. Jin, A. A. A. Kheraif and J. Lin, Chem. Mater., 2019, 31, 2651–2660 CrossRef CAS
.
- Z. Tang, H. Zhang, Y. Liu, D. Ni, H. Zhang, J. Zhang, Z. Yao, M. He, J. Shi and W. Bu, Adv. Mater., 2017, 29, 1701683 CrossRef PubMed
.
- S. Ruan, M. Yuan, L. Zhang, G. Hu, J. Chen, X. Cun, Q. Zhang, Y. Yang, Q. He and H. Gao, Biomaterials, 2015, 37, 425–435 CrossRef CAS PubMed
.
- W. Zhu, Z. Dong, T. Fu, J. Liu, Q. Chen, Y. Li, R. Zhu, L. Xu and Z. Liu, Adv. Funct. Mater., 2016, 26, 5490–5498 CrossRef CAS
.
- Y. Zhang, Y. Xu, D. Sun, Z. Meng, W. Ying, W. Gao, R. Hou, Y. Zheng, X. Cai, B. Hu and X. Lin, Chem. Eng. J., 2020, 390, 124521 CrossRef CAS
.
- X. Yi, L. Chen, X. Zhong, R. Gao, Y. Qian, F. Wu, G. Song, Z. Chai, Z. Liu and K. Yang, Nano Res., 2016, 9, 3267–3278 CrossRef CAS
.
- L. Wang, S. Guan, Y. Weng, S.-M. Xu, H. Lu, X. Meng and S. Zhou, ACS Appl. Mater. Interfaces, 2019, 11, 6267–6275 CrossRef CAS PubMed
.
- S. Wang, F. Li, R. Qiao, X. Hu, H. Liao, L. Chen, J. Wu, H. Wu, M. Zhao, J. Liu, R. Chen, X. Ma, D. Kim, J. Sun, T. P. Davis, C. Chen, J. Tian, T. Hyeon and D. Ling, ACS Nano, 2018, 12, 12380–12392 CrossRef CAS PubMed
.
- L.-S. Lin, J. Song, L. Song, K. Ke, Y. Liu, Z. Zhou, Z. Shen, J. Li, Z. Yang, W. Tang, G. Niu, H.-H. Yang and X. Chen, Angew. Chem., Int. Ed., 2018, 57, 4902–4906 CrossRef CAS PubMed
.
- M. Fan, L. Jia, M. Pang, X. Yang, Y. Yang, S. Kamel Elyzayati, Y. Liao, H. Wang, Y. Zhu and Q. Wang, Adv. Funct. Mater., 2021, 31, 2010587 CrossRef CAS
.
- B. Ding, P. Zheng, P. A. Ma and J. Lin, Adv. Mater., 2020, 32, 1905823 CrossRef CAS PubMed
.
- X. Qian, X. Han, L. Yu, T. Xu and Y. Chen, Adv. Funct. Mater., 2020, 30, 1907066 CrossRef CAS
.
- D. Zhu, X.-H. Zhu, S.-Z. Ren, Y.-D. Lu and H.-L. Zhu, J. Drug Target., 2020 DOI:10.1080/1061186x.2020.1815209
.
- X. Liu, Y. Zhou, W. Xie, S. Liu, Q. Zhao and W. Huang, Small Methods, 2020, 4, 2000566 CrossRef CAS
.
- R. Liang, L. Liu, H. He, Z. Chen, Z. Han, Z. Luo, Z. Wu, M. Zheng, Y. Ma and L. Cai, Biomaterials, 2018, 177, 149–160 CrossRef CAS PubMed
.
- M. Yu, X. Duan, Y. Cai, F. Zhang, S. Jiang, S. Han, J. Shen and X. Shuai, Adv. Sci., 2019, 6, 1900037 CrossRef PubMed
.
- G. Yang, L. Xu, Y. Chao, J. Xu, X. Sun, Y. Wu, R. Peng and Z. Liu, Nat. Commun., 2017, 8, 902 CrossRef PubMed
.
- C.-C. Chang, D. Trinh Kieu, Y.-A. Lee, F.-N. Wang, Y.-C. Sung, P.-L. Yu, S.-C. Chiu, Y.-C. Shih, C.-Y. Wu, Y.-D. Huang, J. Wang, T.-T. Lu, D. Wan and Y. Chen, ACS Appl. Mater. Interfaces, 2020, 12, 44407–44419 CrossRef CAS PubMed
.
- F. Gao, Y. Tang, W.-L. Liu, M.-Z. Zou, C. Huang, C.-J. Liu and X.-Z. Zhang, Adv. Mater., 2019, 31, 1904639 CrossRef CAS PubMed
.
- B. Ding, P. Zheng, F. Jiang, Y. Zhao, M. Wang, M. Chang, P. A. Ma and J. Lin, Angew. Chem., Int. Ed., 2020, 59, 16381–16384 CrossRef CAS PubMed
.
- Y. Yang, Z. Gu, J. Tang, M. Zhang, Y. Yang, H. Song and C. Yu, Adv. Sci., 2020, 8, 2002667 CrossRef PubMed
.
- X. Yang, Y. Yang, J. Bian, J. Wei, Z. Wang, Z. Zhou, Z. Li and M. Sun, Nano Today, 2021, 38, 101109 CrossRef CAS
.
- L. Meng, Y. Cheng, X. Tong, S. Gan, Y. Ding, Y. Zhang, C. Wang, L. Xu, Y. Zhu, J. Wu, Y. Hu and A. Yuan, ACS Nano, 2018, 12, 8308–8322 CrossRef CAS PubMed
.
- C. He, X. Duan, N. Guo, C. Chan, C. Poon, R. R. Weichselbaum and W. Lin, Nat. Commun., 2016, 7, 12499 CrossRef CAS PubMed
.
- D. Wang, T. Wang, J. Liu, H. Yu, S. Jiao, B. Feng, F. Zhou, Y. Fu, Q. Yin, P. Zhang, Z. Zhang, Z. Zhou and Y. Li, Nano Lett., 2016, 16, 5503–5513 CrossRef CAS PubMed
.
- J. Xu, L. Xu, C. Wang, R. Yang, Q. Zhuang, X. Han, Z. Dong, W. Zhu, R. Peng and Z. Liu, ACS Nano, 2017, 11, 4463–4474 CrossRef CAS PubMed
.
- G. Lan, K. Ni, Z. Xu, S. S. Veroneau, Y. Song and W. Lin, J. Am. Chem. Soc., 2018, 140, 5670–5673 CrossRef CAS PubMed
.
- K. Lu, C. He, N. Guo, C. Chan, K. Ni, R. R. Weichselbaum and W. Lin, J. Am. Chem. Soc., 2016, 138, 12502–12510 CrossRef CAS PubMed
.
- A. P. Castano, P. Mroz and M. R. Hamblin, Nat. Rev. Cancer, 2006, 6, 535–545 CrossRef CAS PubMed
.
- H. Chen, J. Tian, W. He and Z. Guo, J. Am. Chem. Soc., 2015, 137, 1539–1547 CrossRef CAS PubMed
.
- Y. Liu, Y. Pan, W. Cao, F. Xia, B. Liu, J. Niu, G. Alfranca, X. Sun, L. Ma, J. M. de la Fuente, J. Song, J. Ni and D. Cui, Theranostics, 2019, 9, 6867–6884 CrossRef CAS PubMed
.
- C.-H. Chung, K.-Y. Lu, W.-C. Lee, W.-J. Hsu, W.-F. Lee, J.-Z. Dai, P.-W. Shueng, C.-W. Lin and F.-L. Mi, Biomaterials, 2020, 257, 120227 CrossRef CAS PubMed
.
- Q. He, Z. Zhang, H. Liu, Z. Tuo, J. Zhou, Y. Hu, Y. Sun, C. Wan, Z. Xu, J. F. Lovell, D. Hu, K. Yang and H. Jin, Nanoscale, 2020, 12, 14788–14800 RSC
.
- Y. Liu, J. Yang, B. Liu, W. Cao, J. Zhang, Y. Yang, L. Ma, J. M. de la Fuente, J. Song, J. Ni, C. Zhang and D. Cui, Nano-Micro Lett., 2020, 12, 127 CrossRef CAS PubMed
.
- Z. Shen, J. Xia, Q. Ma, W. Zhu, Z. Gao, S. Han, Y. Liang, J. Cao and Y. Sun, Theranostics, 2020, 10, 9132–9152 CrossRef CAS PubMed
.
- C. Wang, Y. Xiao, W. Zhu, J. Chu, J. Xu, H. Zhao, F. Shen, R. Peng and Z. Liu, Small, 2020, 16, 2000589 CrossRef CAS PubMed
.
- L. Zhou, L. Chen, X. Hu, Y. Lu, W. Liu, Y. Sun, T. Yao, C. Dong and S. Shi, Commun. Biol., 2020, 3, 343 CrossRef CAS PubMed
.
- I. B. Barsoum, C. A. Smallwood, D. R. Siemens and C. H. Graham, Cancer Res., 2014, 74, 665–674 CrossRef CAS PubMed
.
- M. Z. Noman, G. Desantis, B. Janji, M. Hasmim, S. Karray, P. Dessen, V. Bronte and S. Chouaib, J. Exp. Med., 2014, 211, 781–790 CrossRef CAS PubMed
.
- X. Ai, M. Hu, Z. Wang, L. Lyu, W. Zhang, J. Li, H. Yang, J. Lin and B. Xing, Bioconjugate Chem., 2018, 29, 928–938 CrossRef CAS PubMed
.
- S. Zanganeh, G. Hutter, R. Spitler, O. Lenkov, M. Mahmoudi, A. Shaw, J. S. Pajarinen, H. Nejadnik, S. Goodman, M. Moseley, L. M. Coussens and H. E. Daldrup-Link, Nat. Nanotechnol., 2016, 11, 986–994 CrossRef CAS PubMed
.
- G.-T. Yu, L. Rao, H. Wu, L.-L. Yang, L.-L. Bu, W.-W. Deng, L. Wu, X. Nan, W.-F. Zhang, X.-Z. Zhao, W. Liu and Z.-J. Sun, Adv. Funct. Mater., 2018, 28, 1801389 CrossRef
.
- L. He, T. Nie, X. Xia, T. Liu, Y. Huang, X. Wang and T. Chen, Adv. Funct. Mater., 2019, 29, 1901240 CrossRef
.
- Y. Wang, Y.-X. Lin, S.-L. Qiao, H.-W. An, Y. Ma, Z.-Y. Qiao, R. P. Y. J. Rajapaksha and H. Wang, Biomaterials, 2017, 112, 153–163 CrossRef CAS PubMed
.
- G. Gu, Q. Hu, X. Feng, X. Gao, M. Jiang, T. Kang, D. Jiang, Q. Song, H. Chen and J. Chen, Biomaterials, 2014, 35, 8215–8226 CrossRef CAS PubMed
.
- Z. Wei, P. Liang, J. Xie, C. Song, C. Tang, Y. Wang, X. Yin, Y. Cai, W. Han and X. Dong, Chem. Sci., 2019, 10, 2778–2784 RSC
.
- P. Bhattarai, S. Hameed and Z. Dai, Nanoscale, 2018, 10, 5393–5423 RSC
.
- Y.-j. Zhu, B. Zheng, H.-y. Wang and L. Chen, Acta Pharmacol. Sin., 2017, 38, 614–622 CrossRef CAS PubMed
.
- J. X. Wang, S. Y. C. Choi, X. Niu, N. Kang, H. Xue, J. Killam and Y. Wang, Int. J. Mole. Sci., 2020, 21, 8363 CrossRef CAS PubMed
.
- O. R. Colegio, C. Ngoc-Quynh, A. L. Szabo, T. Chu, A. M. Rhebergen, V. Jairam, N. Cyrus, C. E. Brokowski, S. C. Eisenbarth, G. M. Phillips, G. W. Cline, A. J. Phillips and R. Medzhitov, Nature, 2014, 513, 559–563 CrossRef CAS PubMed
.
- T. Bohn, S. Rapp, N. Luther, M. Klein, T.-J. Bruehl, N. Kojima, P. A. Lopez, J. Hahlbrock, S. Muth, S. Endo, S. Pektor, A. Brand, K. Renner, V. Popp, K. Gerlach, D. Vogel, C. Lueckel, D. Arnold-Schild, J. Pouyssegur, M. Kreutz, M. Huber, J. Koenig, B. Weigmann, H.-C. Probst, E. von Stebut, C. Becker, H. Schild, E. Schmitt and T. Bopp, Nat. Immunol., 2018, 19, 1319–1329 CrossRef CAS PubMed
.
- M. Obeid, A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh, J.-L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Metivier, N. Larochette, P. van Endert, F. Ciccosanti, M. Piacentini, L. Zitvogel and G. Kroemer, Nat. Med., 2007, 13, 54–61 CrossRef CAS PubMed
.
- D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis and P. Vandenabeele, Nat. Rev. Cancer, 2012, 12, 860–875 CrossRef CAS PubMed
.
- J. Lu, X. Liu, Y.-P. Liao, X. Wang, A. Ahmed, W. Jiang, Y. Ji, H. Meng and A. E. Nel, ACS Nano, 2018, 12, 11041–11061 CrossRef CAS PubMed
.
- F. Zhou, B. Feng, H. Yu, D. Wang, T. Wang, Y. Ma, S. Wang and Y. Li, Adv. Mater., 2019, 31, 1805888 CrossRef PubMed
.
- X. Duan, C. Chan and W. Lin, Angew. Chem., Int. Ed., 2019, 58, 670–680 CrossRef CAS PubMed
.
- P. Zheng, B. Ding, Z. Jiang, W. Xu, G. Li, J. Ding and X. Chen, Nano Lett., 2021, 21, 2088–2093 CrossRef CAS PubMed
.
- M. Chang, Z. Hou, M. Wang, C. Li and J. Lin, Adv. Mater., 2020, 33, 2004788 CrossRef PubMed
.
- Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng and Z. Liu, Nat. Commun., 2016, 7, 13193 CrossRef CAS PubMed
.
- Q. Chen, Q. Hu, E. Dukhovlinova, G. Chen, S. Ahn, C. Wang, E. A. Ogunnaike, F. S. Ligler, G. Dotti and Z. Gu, Adv. Mater., 2019, 31, 1900192 CrossRef PubMed
.
- C. W. Ng, J. Li and K. Pu, Adv. Funct. Mater., 2018, 28, 1804688 CrossRef
.
- Z. Liu, S. Zhang, H. Lin, M. Zhao, H. Yao, L. Zhang, W. Peng and Y. Chen, Biomaterials, 2018, 155, 54–63 CrossRef CAS PubMed
.
- L. Zhou, B. Hou, D. Wang, F. Sun, R. Song, Q. Shao, H. Wang, H. Yu and Y. Li, Nano Lett., 2020, 20, 4393–4402 CrossRef CAS PubMed
.
- J. Zhao, S. Ma, Y. Xu, X. Si, H. Yao, Z. Huang, Y. Zhang, H. Yu, Z. Tang, W. Song and X. Chen, Biomaterials, 2021, 268, 120542 CrossRef CAS PubMed
.
- D. Shae, K. W. Becker, P. Christov, D. S. Yun, A. K. R. Lytton-Jean, S. Sevimli, M. Ascano, M. Kelley, D. B. Johnson, J. M. Balko and J. T. Wilson, Nat. Nanotechnol., 2019, 14, 269–278 CrossRef CAS PubMed
.
- A. F. U. H. Saeed, X. Ruan, H. Guan, J. Su and S. Ouyang, Adv. Sci., 2020, 7, 1902599 CrossRef CAS PubMed
.
- M. Lv, M. Chen, R. Zhang, W. Zhang, C. Wang, Y. Zhang, X. Wei, Y. Guan, J. Liu, K. Feng, M. Jing, X. Wang, Y.-C. Liu, Q. Mei, W. Han and Z. Jiang, Cell Res., 2020, 30, 966–979 CrossRef CAS PubMed
.
- C. Wang, Y. Guan, M. Lv, R. Zhang, Z. Guo, X. Wei, X. Du, J. Yang, T. Li, Y. Wan, X. Su, X. Huang and Z. Jiang, Immunity, 2018, 48, 675–687 CrossRef CAS PubMed
.
- L. Hou, C. Tian, Y. Yan, L. Zhang, H. Zhang and Z. Zhang, ACS Nano, 2020, 14, 3927–3940 CrossRef CAS PubMed
.
- B. Ding, S. Shao, C. Yu, B. Teng, M. Wang, Z. Cheng, K.-L. Wong, P. A. Ma and J. Lin, Adv. Mater., 2018, 30, 1802479 CrossRef PubMed
.
- R. Kuai, L. J. Ochyl, K. S. Bahjat, A. Schwendeman and J. J. Moon, Nat. Mater., 2017, 16, 489–496 CrossRef CAS PubMed
.
- S.-Y. Liu, W. Wei, H. Yue, D.-Z. Ni, Z.-G. Yue, S. Wang, Q. Fu, Y.-Q. Wang, G.-H. Ma and Z.-G. Su, Biomaterials, 2013, 34, 8291–8300 CrossRef CAS PubMed
.
- S. C. Eisenbarth, O. R. Colegio, W. O'Connor, Jr., F. S. Sutterwala and R. A. Flavell, Nature, 2008, 453, 1122–1126 CrossRef CAS PubMed
.
- T. L. Flach, G. Ng, A. Hari, M. D. Desrosiers, P. Zhang, S. M. Ward, M. E. Seamone, A. Vilaysane, A. D. Mucsi, Y. Fong, E. Prenner, C. C. Ling, J. Tschopp, D. A. Muruve, M. W. Amrein and Y. Shi, Nat. Med., 2011, 17, 479–487 CrossRef CAS PubMed
.
- Y. Wang, Y. Xie, J. Luo, M. Guo, X. Hu, X. Chen, Z. Chen, X. Lu, L. Mao, K. Zhang, L. Wei, Y. Ma, R. Wang, J. Zhou, C. He, Y. Zhang, Y. Zhang, S. Chen, L. Shen, Y. Chen, N. Qiu, Y. Liu, Y. Cui, G. Liao, Y. Liu and C. Chen, Nano Today, 2021, 38, 101139 CrossRef CAS PubMed
.
Footnote |
† Binbin Ding and Jun Yue contributed equally to this work. |
|
This journal is © The Royal Society of Chemistry 2021 |